Showing 6261-6270 of 7932 results for "".
- South Florida Women's Shelter Dedicates Shade Structureshttps://practicaldermatology.com/news/south-florida-womens-shelter-dedicates-shades-structures/2460992/Aid to Victims of Domestic Abuse, Inc. (AVDA) in Delray Beach, FL dedicated its new shade structure at the Casa Vegso Residential Campus last month. The structure was funded by an American Academy of Dermatology Shade Structure Grant and SafeSun, Inc., a nonprofit organization dedicated to the pr
- Derms Give Back: Caring for Veteranshttps://practicaldermatology.com/news/derms-give-back-caring-for-veterans/2460989/Caring for veterans inspires dermatologists like Joshua E. Lane, MD every single day. Dr. Lane practices in Columbus, GA, near Fort Benning, a large military base, and many of his patients are veterans. He was so moved by their service and selflessness that he joined the
- National Rosacea Society Awards 2021 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2021-research-grants/2460988/The National Rosacea Society has awarded funding for two new studies in addition to continuing support for two ongoing studies as part of its
- With New Agreement, DermTech Melanoma Test Available Through DermatologistOnCallhttps://practicaldermatology.com/news/with-new-agreement-dermtech-melanoma-test-available-through-dermatologistoncall/2460987/The DermTech Melanoma Test is now available through DermatologistOnCall’s telemedicine platform. The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via t
- PsA Treatment Snapshot: Study Highlights Trends in PsA Treatment Since 2018https://practicaldermatology.com/news/psa-treatment-snapshot-study-highlights-trends-in-psa-treatment-since-2018/2460985/There’s been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for psoriatic arthritis (PsA) since 2018, which may reflect their inclusion as potential initial therapy in the American College of Rheumatology/National Pso
- Nearly One Third of Lupus Patients Show Low Responses to COVID-19 Vaccineshttps://practicaldermatology.com/news/nearly-one-third-of-lupus-patients-show-low-responses-to-covid-19-vaccines/2460980/Nearly 30 percent of lupus patients with had a low response to the new COVID-19 vaccines, finds research presented at ACR Convergence, the American College of Rheumatology’s annual meeting. Since Phase III clinical trials of COVID-19 vaccines excluded people who take im
- FDA Fast Tracks Union Therapeutics' AD Candidatehttps://practicaldermatology.com/news/fda-fast-tracks-union-therapeutics-ad-candidate/2460978/The US Food and Drug Administration (FDA) has granted Fast Track designation to Union Therapeutics’ oral orismilast for the treatment of moderate to severe atopic dermatitis (AD). Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properti
- University of Arkansas Researcher Scores $1.6M NIH Grant for Research on Chronic Skin Woundshttps://practicaldermatology.com/news/puniversity-of-arkansas-researcher-scores-16m-nih-grant-for-research-on-chronic-skin-wounds/2460976/University of Arkansas biomedical engineering professor Kyle Quinn received a four-year, $1.6 million grant from the National Institutes of Health to develop non-invasive, real-time “optical biopsies” of chronic skin wounds. The goal is to provide digital histopathology imag
- CeraVe Releases New "Think Ceramides!" Digital Campaignhttps://practicaldermatology.com/news/cerave-releases-new-think-ceramides-digital-campaign/2460975/In support of National Healthy Skin Month this November, CeraVe announces is launching its new "Think Ceramides!" digital campaign. The brand's latest omni-channel initiative focuses on the importance and benefits of ceramides, which are included within all CeraVe pr
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea